Intranasal medication administration delivers drugs through the lining of the nasal cavity, offering a needle-free route that can get certain medications into the bloodstream or even directly into the brain within minutes. The approach has moved well beyond allergy sprays and decongestants: emergency responders now carry intranasal naloxone to reverse opioid overdoses, psychiatrists prescribe an intranasal ketamine derivative for treatment-resistant depression, and researchers are developing nasal vaccines that trigger immune defenses right where respiratory viruses first land. What makes the nose such a versatile drug-delivery site comes down to its unusual anatomy and rich blood supply, but those same features also impose real limits on what can be delivered this way and how well it works.
Why the Nose Works as a Drug Gateway
The inside of your nose is lined with a thin, highly vascularized mucous membrane. Blood vessels sit close to the surface, which means drugs deposited on this tissue can pass into the bloodstream quickly without first traveling through the stomach and liver. That bypass of the digestive tract, sometimes called avoiding “first-pass metabolism,” is a big deal for medications that would otherwise be broken down before they ever reached therapeutic levels. The nasal cavity also contains the endings of two cranial nerves, the olfactory nerve and the trigeminal nerve, that run directly from the upper nose into the brain. Drugs can travel along these nerve pathways to reach brain tissue without needing to cross the blood-brain barrier, the tightly sealed network of cells that normally keeps most circulating substances out of the central nervous system.1PubMed. Mechanism of intranasal drug delivery directly to the brain
This nose-to-brain route has generated enormous interest for neurological and psychiatric conditions where getting enough drug past the blood-brain barrier has been a longstanding obstacle.2PubMed Central. The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases Still, the nasal cavity is relatively small. Its surface area for absorption is modest, which limits how much medication you can put in at once. Most nasal spray devices deliver somewhere around 100 to 200 microliters per nostril, so the drug has to be concentrated enough to fit a therapeutic dose into a tiny volume.
The Mucociliary Clearance Problem
Your nose has a built-in self-cleaning system. A thin layer of mucus coats the nasal lining, and millions of tiny hair-like structures called cilia beat in coordinated waves to sweep that mucus, along with trapped dust, pathogens, and anything else that lands there, toward the back of the throat to be swallowed. This mucociliary clearance is great for keeping your airways healthy, but it works against nasal drug delivery by rapidly flushing medication out of the nose before it has time to be absorbed.3PubMed. The nasal mucociliary clearance: relevance to nasal drug delivery
How quickly a drug gets cleared depends on where it lands in the nose and the properties of the formulation. Standard aqueous sprays can be swept away in minutes. Researchers have tackled this with mucoadhesive polymers, materials that cling to the nasal mucus layer and resist being swept away, giving the drug a longer window to cross into the tissue.4PubMed Central. A review on mucoadhesive polymer used in nasal drug delivery system Gel-based formulations, powder sprays, and microspheres are all strategies designed to keep the drug where it needs to be long enough to work. Even so, optimizing the balance between staying power and comfort remains one of the central challenges of nasal formulation design.5PubMed. Nasal mucociliary clearance as a factor in nasal drug delivery
Devices and Droplet Size Matter More Than You’d Think
Not all nasal sprays are created equal, and the device you use has a meaningful impact on where the medication actually ends up. Traditional pump sprays deposit most of their payload in the front of the nose, near the nasal valve. That is fine for treating congestion or allergy symptoms in the anterior cavity, but it is not ideal for drugs that need to reach deeper or higher regions where absorption is better or where the olfactory nerve endings sit.
A cadaver study comparing several device types found that atomizing devices like the mucosal atomization device (MAD) and a specialized spray-sol system delivered medication significantly better to the middle turbinate, a deeper structure in the nasal cavity, compared with conventional sprays.6PubMed Central. Nasal Delivery Devices: A Comparative Study on Cadaver Model Droplet size plays into this as well. Spray cone angle, insertion angle, and how forcefully you press the actuator all influence particle size distribution and where those droplets settle.7PubMed Central. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions Very fine mists risk being inhaled past the nose and into the lungs, while overly large droplets tend to drip back out or pool at the front. Getting this right is not trivial, and there is active engineering work on devices that optimize deposition for specific target zones within the nasal cavity.8PubMed. Measurements of droplet size distribution and analysis of nasal spray atomization from different actuation pressure
A pediatric study comparing atomized midazolam to nasal drops drove this point home in a clinical setting. Children in the atomized group accepted the medication far more readily and showed faster onset of sedation, with significantly higher sedation scores at five minutes, compared to those who received drops. Adverse events were comparable between the groups.9Saudi Journal of Anaesthesia. A comparative study to assess the efficacy of atomized versus drops administration of intranasal midazolam as premedication in pediatric patients undergoing elective surgery under general anesthesia The practical lesson: delivery method is not just an engineering detail. It changes how well patients tolerate the drug and how quickly it takes effect.
Emergency Medicine Applications
Some of the most impactful uses of intranasal medications are in emergencies, situations where speed matters and starting an IV line may be difficult or impossible. Three drugs in particular have transformed emergency care by going nasal.
Naloxone for opioid overdose is the best-known example. Narcan, the branded nasal spray, puts a 4 mg dose of naloxone into the hands of bystanders with no medical training. Pharmacokinetic work in healthy volunteers showed that a 2 mg intranasal dose achieved comparable early blood levels to a standard 0.4 mg intramuscular injection, and then maintained plasma concentrations at roughly the equivalent of two intramuscular doses for more than two hours.10PubMed Central. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study That prolonged effect matters because some synthetic opioids outlast a single intramuscular dose. The tradeoff is that intranasal bioavailability is lower, about 75% relative to intramuscular injection for a similar dose, so intranasal products compensate by using a higher milligram dose.11PubMed. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers
Midazolam for acute seizures has shifted treatment of prolonged seizures in children, both in emergency departments and at home. For years, rectal diazepam was the go-to option for parents and paramedics who needed to stop a seizure before reaching a hospital. Intranasal midazolam has emerged as a less invasive, more dignified alternative that parents can administer without specialized equipment.12PubMed Central. Treatment of acute seizures: is intranasal midazolam a viable option? The drug absorbs quickly through the nasal mucosa, and the speed advantage over a rectal route that many children and caregivers find distressing has been a meaningful quality-of-life improvement.
Intranasal pain relief is another growing area. Two randomized trials in children with suspected limb fractures compared intranasal ketamine to intranasal fentanyl. Both found similar pain reduction between the two drugs, though ketamine was associated with more minor side effects such as a bad taste and dizziness.13PubMed. Randomized Controlled Feasibility Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children with Suspected Extremity Fractures14PubMed. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries Having effective pain management that can be given without needles is especially valuable in pediatric emergencies, where establishing IV access in a screaming, moving child is often slow and traumatic.
Brain-Targeted Therapies for Psychiatric and Neurological Conditions
The nose-to-brain pathway has opened doors for drugs that struggle to reach the central nervous system by any other route. Esketamine nasal spray, approved for treatment-resistant depression, is probably the most prominent commercial product in this category. By spraying a form of ketamine directly into the nose, the drug reaches the brain rapidly enough to produce effects within hours rather than the weeks typically needed for oral antidepressants. Patients self-administer it in a clinical setting under supervision.
Intranasal insulin is a more surprising example. In healthy volunteers, repeated intranasal insulin administration improved memory and mood without changing blood sugar or circulating insulin levels, suggesting the drug was reaching the brain directly rather than entering the systemic circulation in meaningful amounts.15PubMed. Intranasal insulin improves memory in humans Animal studies showed that insulin applied at the level of the cribriform plate (the thin bone separating the top of the nose from the brain) distributed throughout the brain and reversed learning and memory deficits in an Alzheimer’s disease mouse model, again without peripheral metabolic effects.16PubMed Central. Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition This work is still in the research phase for Alzheimer’s, but it illustrates a broader principle: intranasal delivery can put substances into the brain that would be useless or dangerous if they first had to circulate through the whole body.
Intranasal oxytocin has received attention for its potential effects on social behavior and emotional processing. Neuroimaging research suggests that brain regions influenced by intranasal oxytocin show higher expression of the oxytocin receptor, indicating that the effects may involve direct activation of central receptors rather than some indirect mechanism.17bioRxiv. Brain Areas Affected by Intranasal Oxytocin Show Higher Oxytocin Receptor Expression The enthusiasm around intranasal oxytocin for conditions like autism spectrum disorder has been tempered by inconsistent results across trials, but the delivery concept itself remains an active area of investigation.
A recent study explored a two-phase flow atomization device for delivering dexmedetomidine, a sedative, through the nose. The researchers inferred from the drug’s rapid onset of sedation that the device enhanced drug deposition in the olfactory region, potentially facilitating nose-to-brain delivery.18PubMed Central. Safety, pharmacokinetics, and pharmacodynamics of Dexmedetomidine two-phase flow atomization in healthy subjects: a randomized, parallel study This hints at a future where device engineering and drug formulation are jointly optimized to target specific brain regions through the nose.
Nasal Vaccines and Mucosal Immunity
Most injectable vaccines are excellent at generating circulating antibodies in the blood but less effective at building defenses right at the mucosal surfaces where respiratory viruses first invade, namely the nose and lungs. Intranasal vaccines aim to fill that gap by stimulating the production of secretory IgA, a type of antibody specifically adapted to work on mucous membranes. In principle, secretory IgA could neutralize a virus at the point of entry, potentially preventing infection altogether rather than just reducing the severity of disease after the virus has already gained a foothold.
Animal studies have demonstrated the concept. In one study, an intranasal vaccine formulated with an adjuvant induced both systemic IgG antibodies and secretory IgA antibodies in the nasal mucosa, and the IgA response showed cross-reactivity against multiple SARS-CoV-2 variants.19PubMed Central. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology Separate research using albumin-fused subunit vaccines delivered intranasally in mouse models confirmed the dual antibody response, detecting robust antigen-specific IgA in the fluid lining the lungs alongside the expected systemic IgG.20Nature Communications. An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
Several intranasal COVID-19 and influenza vaccines have reached human trials or received limited-use authorization in various countries, though none has yet become a primary-series vaccine in the United States or Europe. The challenge is not just proving that the vaccine works but proving that it works consistently across the wide range of nasal anatomies, mucosal conditions, and clearance rates that exist among different people. Nasal congestion from a cold, allergies, or even dry indoor air can alter how well a nasal vaccine contacts the mucosa.
Systemic Hormone Delivery Through the Nose
Before the brain-targeting research took off, intranasal delivery had already proved its worth for certain peptide hormones that are poorly absorbed when swallowed. Desmopressin, a synthetic version of the hormone vasopressin used to treat conditions like diabetes insipidus and bedwetting, has been available as a nasal spray for decades. Early pharmacokinetic work showed that delivery technique matters a great deal with this drug: splitting the dose into two separate 50-microliter sprays rather than delivering it as a single 100-microliter volume nearly doubled the bioavailability, from about 9% to 20%.21PubMed. Effects of concentration and volume on nasal bioavailability and biological response to desmopressin The clinical effect tracked with this difference. This finding underscored a broader point about intranasal drugs: the volume delivered per spray matters, and more drug in a bigger spray is not necessarily better. Smaller, more concentrated volumes tend to stay on the absorptive surface instead of dripping down the throat.
Other peptide drugs that have used the nasal route include calcitonin (for osteoporosis, though now largely replaced by other therapies) and nafarelin and buserelin, which are gonadotropin-releasing hormone analogs used in reproductive medicine and endometriosis treatment. These drugs survive long enough on the nasal mucosa to be absorbed in clinically useful amounts, something that would not happen in the stomach.
Safety Considerations and Preservative Concerns
Intranasal medications are generally well tolerated for short-term use, but chronic or repeated use raises some specific concerns. Many multi-dose nasal spray formulations contain benzalkonium chloride (BAC) as a preservative to prevent microbial contamination. Research on BAC found that it is directly toxic to the cilia that drive mucociliary clearance. In testing, BAC caused immediate nasal irritation, a burning sensation, and excess mucus production, along with persistent irritation even after the exposure ended.22PubMed. Nasal toxicity of benzalkonium chloride Over time, repeated damage to the cilia could impair the nose’s ability to clear pathogens and debris, potentially increasing susceptibility to infections.
This concern has driven the development of preservative-free formulations, particularly for drugs meant to be used daily over months or years, such as intranasal corticosteroids for allergic rhinitis. Some newer devices use filtered air or one-way valve systems to keep the solution sterile without chemical preservatives. If you use a nasal spray regularly, checking whether the product is preservative-free is worth the effort, especially for long-term use.
Beyond preservatives, irritation or nosebleeds are the most commonly reported side effects of intranasal drugs in general. These are usually related to poor spray technique, such as aiming the nozzle at the septum (the wall between the nostrils) rather than toward the outer wall. Proper technique, aiming slightly outward and away from the midline, reduces contact with the more delicate septal tissue.
How Technique Affects Outcomes
A surprising number of people who use nasal sprays regularly are doing it wrong, and even healthcare providers often lack clear training on optimal technique. A review examining intranasal steroid use found a lack of solid evidence establishing one best method, but an expert panel recommended a standardized seven-step approach that emphasized head positioning, nozzle angle, and gentle inhalation during spraying.23Otolaryngology–Head and Neck Surgery. Techniques of Intranasal Steroid Use The general principles apply across most nasal medications:
- Clear the nose first: Blow gently before spraying so the medication contacts mucosa, not a layer of mucus.
- Angle the nozzle outward: Point it toward the ear on the same side, not straight up or toward the septum. This helps deposit the drug on the lateral nasal wall where absorption is better and irritation is lower.
- Use the opposite hand: Spraying the left nostril with the right hand (and vice versa) naturally angles the nozzle away from the septum.
- Breathe gently: A sniff-like inhalation during actuation can help draw the spray deeper, but forceful inhalation sends droplets past the nose and into the throat or lungs.
- Avoid sneezing it out: Keep the mouth closed and breathe through the nose gently for a few seconds afterward.
These details feel minor but can meaningfully change how much drug reaches the target tissue. The desmopressin study mentioned earlier, where splitting a dose into two smaller sprays nearly doubled bioavailability, is a case in point. The instructions that come in the box are often vague, and a quick conversation with a pharmacist is worth having if you are starting a new intranasal medication.
Emerging Nanotechnology Approaches
Much of the next-generation research in intranasal delivery involves nanoparticles and nanocarriers, tiny engineered vehicles that package drugs at the molecular scale. The goals are straightforward even if the engineering is not: keep the drug on the nasal mucosa longer, protect it from enzymatic breakdown, and help it cross the mucosal barrier more efficiently. Nanocarrier systems including liposomes, polymeric nanoparticles, and lipid-based particles are being explored for nose-to-brain delivery of everything from small-molecule drugs to gene therapies for neurological disorders.24PubMed Central. Recent Advances in Nose-to-Brain Gene Delivery for Central Nervous System Disorders
The promise is real, but the gap between animal studies and approved human therapies in this space remains wide. Most nanocarrier systems for intranasal delivery are still in preclinical testing. Regulatory agencies have not yet established clear long-term safety standards for repeated nasal exposure to nanoparticles, and the nasal mucosa’s sensitivity means that what looks safe in a short-term rodent study may cause problems in humans after months of daily use. The field acknowledges that well-designed clinical studies are needed to establish the long-term safety and efficacy of these approaches before they can move into routine practice.
Gene therapy delivery through the nose is one of the more ambitious applications under investigation. The idea is to use nanocarriers to ferry DNA or RNA-based therapeutics along the olfactory pathway into brain tissue, potentially treating conditions like Parkinson’s disease or glioblastoma at their source. These concepts are early-stage, but they represent the logical extension of the same anatomical pathway that already enables intranasal naloxone and esketamine to work.